Is Guardant Health Inc (GH) overvalued? · rev $739.0M
Guardant Health Inc (GH) is a diagnostics & research company listed on US.
This page asks whether Guardant Health Inc (GH) looks expensive on cached numbers — not a short thesis.
Latest reported GH revenue for 2024-12-31 was $739.0M. Net income was -$436.4M. Revenue was up 31.0% from 2023-12-31 to 2024-12-31. GH currently screens at market cap $6.32B.
GH currently screens at market cap $6.32B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next GH 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the GH stock page for the full model, not this heading.
Not investment advice.